FutureGen Biopharm
http://www.futuregen.com.cn/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From FutureGen Biopharm
AbbVie Cranks Up Temperature In IBD Market With Celsius Buyout
The drug maker is spending $250m to acquire privately held Celsius and its lead candidate, a monoclonal antibody targeting TREM1 in inflammatory bowel disease.
AbbVie Doubles Down In IBD With Skyrizi Ulcerative Colitis Approval
The US major's blockbuster is already well established as a treatment for Crohn’s disease but the latest thumbs-up from the US FDA means Skyrizi is the first interleukin-23 inhibitor approved for both principal types of inflammatory bowel disease.
AbbVie Adds IBD Candidate In Deal With China’s FutureGen
Deal snapshot: AbbVie joins peers Merck & Co., Roche and Pfizer with a TL1A-targeted antibody for potential therapy in inflammatory bowel disease, paying $150m up front.
Asia Deal Watch: Incyte Inks Chinese Marketing Partnership With InnoCare For Monjuvi
Gracell and FutureGen and NovaRock and Flame partner in Claudin 18.2 antibody R&D for cancer. Plus deals involving HDT Bio/Quratis, Pfizer China/Ferring and Antengene/MindRank AI.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice